NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), which is focused on developing new predictive tests and targeted therapeutics from its growing portfolio of proprietary genetic biomarkers, today reported strong results for the Company’s fiscal second quarter ended September 30, 2007, and significant progress against its key milestones.
